OTLK - Outlook Therapeutics: Likely FDA Approval, Possible
Jan 22, 2022 · To top it off, OTLK has seen significant, informational insider buying in the past few months. Buyers include the CEO, CFO, COO, CCO, and Sukhtian Ghiath (both directly and through Jordan-based holding company GMS Tenshi Holdings), who is the chairman of MS Pharma, among numerous other roles .
OTLK - Announces Strategic Organizational Realignment
ISELIN, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve U.S. Food and Drug Administration (FDA) approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced a realignment of resources.
OTLK - Outlook Therapeutics® Announces Effective Date for 1
ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective …
r/OTLK_Investors - Reddit
otlk - schedule 14a (rule 14a-101) notice of special meeting of stockholders. u/pfelgueiras. admin mod ...
OTLK - SCHEDULE 14A INFORMATION - NOTICE OF ANNUAL …
Feb 8, 2024 · NOTICE OF ANNUAL MEETING OF STOCKHOLDERS Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders of Outlook Therapeutics, Inc., a Delaware corporation.
OTLK - Outlook Therapeutics® (NASDAQ: OTLK) to Participate
Jun 13, 2024 · Live webcast today at 4:00 PM ET June 13, 2024. Greetings, We hope you will be able to join us for the Virtual Investor Closing Bell Series with Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina …
OTLK - Receives European Union Positive CHMP Opinion for ONS …
ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
OTLK - SCHEDULE 13G : r/OTLK_Investors - Reddit
OTLK - SEC FORM 8-K On April 1, 2024 OTLK Regained NASDAQ Compliance regarding minimum bid price $1.00 ...
Hold on to Outlook Therapeutics ($OTLK) as Analysts ... - Reddit
Nov 4, 2023 · Considering the fluctuating performance of OTLK, short-term price movements may follow a positive trajectory since technical indicators such as the MACD and traded volume are showing bullish signs. On the other side, the fundamental analysis reveals that the company is operating at a loss and the wide gap between the 200-day moving average and ...
OTLK - Outlook Therapeutics ends 1Q with cash and equivalents
Feb 15, 2023 · Outlook Therapeutics Inc (NASDAQ:OTLK) announced that it has ended its first quarter of fiscal 2023 with cash and equivalents of $52.3 million as of December 31, 2022, which the company says is expected to provide sufficient capital to support operations past the anticipated US Food & Drug Administration (FDA) approval of ONS-5010 in the third calendar …